MOTS-c
Mitochondrial-derived peptide
MOTS-c is a 16-amino-acid peptide encoded by your own mitochondrial DNA — a 'mitochondrial-derived peptide' first identified in 2015. It's one of the most exciting research compounds in the metabolism and longevity space because it behaves like an <b>exercise mimetic</b>: it activates the same AMPK energy pathway that physical activity does. This guide covers how MOTS-c works, what the research shows, dosing references, safety and legal status.
MOTS-c quick facts
| Reported research dosing | 1mg-5mg |
| Route | Either |
| Cycle length | 4-16 Weeks |
| Frequency | 1x Daily · 5 On 2 Off or Daily |
| Half-life | Short (minutes-hours) |
| Forms | Injectable |
| Evidence level | Animal + early human |
Metabolic/energy peptide. Pre-training timing is where people feel it.
How MOTS-c works
MOTS-c's central action is activating AMPK — the cell's master 'low-energy' switch — but it does so through an elegant route: it disrupts the folate cycle (inhibiting AICAR transformylase), which causes AICAR to accumulate inside the cell, and AICAR is itself a potent AMPK activator (the same intermediate researchers use to mimic exercise in animals). Once AMPK is on, cells increase glucose uptake, ramp up fat oxidation, encourage mitochondrial biogenesis, and shut down energy-wasting pathways. MOTS-c also travels to the nucleus under stress to switch on stress-adaptation genes.
What the research shows — the 'exercise in a vial' idea
MOTS-c is naturally produced in response to exercise and stress, and its levels fall with age — which is a big part of why it's studied for metabolic and longevity applications. In animal models, MOTS-c treatment has improved endurance, enhanced fat oxidation and improved glucose metabolism and insulin sensitivity. It's important to be honest, though: MOTS-c shares key molecular signaling with exercise, but it does not replicate all the benefits of actually training — think of it as one lever exercise pulls, not a replacement for it.
The honest state of human evidence
The compelling MOTS-c data is largely preclinical (animal and cell). Human use is currently off-label and extrapolated from that animal work, without large controlled human trials behind it. It's a genuinely promising research peptide — but promising is not the same as proven, and biomarker monitoring and professional supervision matter.
MOTS-c dosing (research reference)
There is no single established MOTS-c dose — the research and practitioner literature references different strategies depending on the goal (metabolic health vs fat loss vs performance), typically as a subcutaneous injection reconstituted with bacteriostatic water. The calculator above converts a research amount into syringe units. This is a summary of existing references for education only, not dosing advice or a recommendation for human use.
Safety & side effects
As a peptide identical to one your body already makes, MOTS-c is generally described as well tolerated in the available research, but controlled long-term human safety data is lacking. Because it acts on glucose and energy metabolism, anyone with blood-sugar considerations should be especially careful, and research-market purity varies — third-party testing matters.
Related compounds
MOTS-c sits alongside other metabolic and mitochondrial tools like NAD+ and the AMPK/exercise-mimetic small molecules. It's frequently discussed in longevity and body-composition protocols rather than used in isolation.
Legal & regulatory status
MOTS-c is not FDA-approved and is sold as a research compound (research use only). Its status, like other peptides, is subject to ongoing FDA review. Follow the laws and any sport-testing rules that apply to you.
✅ Clinically validated
- No completed randomised human trials, but this is a compound where that is a statement about the calendar rather than about the molecule — human work is underway and the position may change.
- Early human work exists on the peptide's biology — circulating MOTS-c falls with age and with insulin resistance in human cohorts — but no randomised trial of administering it.
📊 Correlative data
- Human observational data is about the ENDOGENOUS peptide, not the injected one: higher circulating MOTS-c associates with better insulin sensitivity, and one study found it elevated in long-lived Japanese cohorts. That is a correlation about your own physiology and says nothing directly about supplementing it.
- Used in practice for metabolic and endurance goals with reports of improved training capacity. Beyond that, the record is self-reported. Community dosing logs are real information about tolerability and nothing at all about efficacy: nobody posts the cycle where they felt no different, so what survives is a filtered sample that will always look better than the truth.
🧪 Theoretical / extrapolated
- A mitochondrial-derived peptide — encoded in mitochondrial rather than nuclear DNA, which is genuinely unusual. It activates AMPK and shifts cells toward glucose utilisation and fatty-acid oxidation.
- Rodent work shows improved insulin sensitivity and exercise capacity, and prevention of diet-induced obesity. The AMPK mechanism predicts the practical read: it should behave like an exercise mimetic, which means the effect is largest in someone metabolically unwell and smallest in someone already training hard.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
MOTS-c — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These act on mitochondrial function, NAD+ availability, sirtuin signalling or cellular clearance. The honest prediction is that acute harm is unlikely and the interesting risks are theoretical and long-range — which is a different shape of risk, not an absence of one.
- Growth and clearance signals cut both ways. Anything that improves the efficiency of cell survival is also improving it for cells you would rather not keep. Anything that pushes clearance hard is doing so indiscriminately.
- The near-term, practical ones: NAD+ precursors and infusions commonly cause flushing and a strong sensation if pushed fast, and several compounds in this class are stimulating enough to disrupt sleep.
What has actually been reported
- Generally well tolerated at studied doses. NAD+ infusion discomfort is rate-dependent and resolves by slowing down.
- The human evidence is mostly short trials with surrogate endpoints — a marker moved, not a life changed. That is worth knowing before you build a decade-long habit on it.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Slow the infusion rate. Almost all NAD+ discomfort is rate, not dose. There is no prize for finishing quickly.
- Dose earlier in the day. Several of these are subtly stimulating, and sleep is where most of the repair you are paying for happens.
- Pick an endpoint you can actually measure, and take the baseline before you start. This is the class most prone to spending years on something with no way of knowing whether it did anything.
- Fix the basics first. Sleep, training and bloodwork move the same markers further than anything on this list, and they are free. A longevity compound stacked on four hours of sleep is a rounding error.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- There is no NAD+ assay worth ordering clinically. Judge this class on downstream markers — inflammatory markers, lipids, fasting glucose, and whatever your baseline panel showed as out of range.
Don't run this if
- Active malignancy, for the survival-signalling reasoning above.
- Pregnancy — uncharacterised.
The honest unknown
- Whether any of it extends healthspan in humans. Every honest person in this field is running on mechanism and animal data, and this catalogue should say so rather than imply otherwise.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Close to the tissue, and consistency beats the clock — fasted
A brief exposure starts a process that runs for days, so the hour you dose is a minor variable — missing days is the one that costs you. Where the target is local, dosing near the site is worth more than any timing choice.
The fasted flag on this one is real: food blunts absorption enough to matter.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
MOTS-c reconstitution calculator
Research reconstitution calculator
Where to get MOTS-c
Buy MOTS-c at AminoWell USA →MOTS-c — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What MOTS-c moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- hs-CRP (High-Sensitivity C-Reactive Protein) — ↓ expected to fall
Where these work, systemic inflammation is the plausible readout.
What to do: hs-CRP is cheap and moves. Baseline and 12 weeks. - HbA1c (Hemoglobin A1c) — ↓ expected to fall
Improved mitochondrial and metabolic function should show here if the effect is real at all.
What to do: The honest use of these markers is as a falsification test: if nothing moves in 12 weeks, the compound is not doing much for you. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Liver and kidney function — the standard baseline for anything run long term.
What to do: Twice a year is enough on a stable protocol.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for MOTS-c — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.
Bloodwork to run alongside MOTS-c
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | A mitochondrial peptide aimed squarely at metabolic health |
| Fasting Insulin | Where the effect should appear first |
| Comprehensive Metabolic Panel (CMP) | Fasting glucose, liver and kidney |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Inflammation baseline |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 102 markers A–Z
MOTS-c — frequently asked questions
What is MOTS-c?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded by mitochondrial DNA and discovered in 2015. It's researched for metabolism, insulin sensitivity and as an 'exercise-mimetic' compound.
How does MOTS-c work?
It activates AMPK — the cell's energy-sensing switch — by causing AICAR to accumulate, which boosts glucose uptake, fat oxidation and mitochondrial biogenesis, mirroring some of exercise's molecular signaling.
Is MOTS-c really 'exercise in a vial'?
It shares key signaling with exercise (AMPK activation) and improved endurance and fat oxidation in animals, but it does not replicate all of exercise's benefits. It's a research tool, not a replacement for training.
Does MOTS-c work in humans?
Most evidence is preclinical (animal/cell). Human use is off-label and extrapolated, without large controlled human trials, so it should be treated as an experimental research peptide with proper monitoring.
How is MOTS-c dosed?
There's no single established dose; the literature references different strategies by goal, as a subq injection reconstituted with bacteriostatic water (see the calculator above). This is educational, not dosing advice.
Is MOTS-c FDA-approved?
No. MOTS-c is not FDA-approved and is sold as a research compound, with status subject to ongoing FDA review.
References & further reading
- MOTS-c: effects and mechanisms in stress, metabolism and aging (PMC)
- MOTS-c as an exercise-mimetic peptide — research overview
- MOTS-c research profile & guide (Peptides Institute)
Want Coach Cam's exact MOTS-c protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What MOTS-c is used for
MOTS-c appears under 5 goals in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.